KR102413920B1 - Hangover-relieving composition comprising fermented black radish - Google Patents
Hangover-relieving composition comprising fermented black radish Download PDFInfo
- Publication number
- KR102413920B1 KR102413920B1 KR1020210071759A KR20210071759A KR102413920B1 KR 102413920 B1 KR102413920 B1 KR 102413920B1 KR 1020210071759 A KR1020210071759 A KR 1020210071759A KR 20210071759 A KR20210071759 A KR 20210071759A KR 102413920 B1 KR102413920 B1 KR 102413920B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- relieving
- hangover
- lactic acid
- acid bacteria
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 206010019133 Hangover Diseases 0.000 title claims abstract description 29
- 241000220259 Raphanus Species 0.000 title claims description 38
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 title claims description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 241000894006 Bacteria Species 0.000 claims abstract description 30
- 239000004310 lactic acid Substances 0.000 claims abstract description 30
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 230000000694 effects Effects 0.000 claims description 49
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 27
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 4
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 26
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 25
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 22
- 238000002835 absorbance Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 210000005228 liver tissue Anatomy 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 229940092385 radish extract Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 206010024585 Lipidosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019057 Raphanus caudatus Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000011380 Raphanus sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A23Y2220/17—
-
- A23Y2220/39—
-
- A23Y2220/67—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 검정무 유산균 발효물을 포함하는 숙취 해소용 조성물에 관한 것이다.The present invention relates to a composition for relieving a hangover comprising a fermented black-free lactic acid bacteria.
Description
본 발명은 검정무 유산균 발효물을 포함하는 숙취 해소용 조성물에 관한 것이다.The present invention relates to a composition for relieving a hangover comprising a fermented black-free lactic acid bacteria.
과다한 알코올 섭취는 신체의 거의 모든 부분에 영향을 미쳐, 간질환, 위염, 췌장염, 고혈압, 중풍, 당뇨병, 심장병 등 많은 질환의 원인이 되고, 갈증, 전신권태, 피로감, 기억상실, 복부 팽만감, 소화 불량, 구토 설사, 비타민 결핍 등의 숙취 현상과 알코올 중독의 위험성까지 많은 부작용을 야기한다.Excessive alcohol intake affects almost all parts of the body, causing many diseases such as liver disease, gastritis, pancreatitis, high blood pressure, stroke, diabetes, heart disease, thirst, general malaise, fatigue, memory loss, abdominal bloating, and digestion. It causes many side effects, including hangover symptoms such as malnutrition, vomiting, diarrhea, vitamin deficiency, and the risk of alcohol poisoning.
이 중 숙취 현상은 체내에 축적된 알코올 및 아세트알데하이드의 작용에 의해 발생하는 것으로 알려져 있다. 간장 내로 들어온 에탄올은 세포 시토졸 내의 알코올 탈수소 효소(alcohol dehydrogenase, ADH)에 의해 아세트알데하이드로 전환된 후, 알데하이드 탈수소 효소(aldehyde dehydrogenase, ALDH)의 작용에 의해 아세테이트로 전환되고, 이는 순환계를 통해 간세포 밖으로 배설된다. 상기 대사 과정에서 에탄올의 최초 대사 산물로서 생성되는 아세트알데하이드는 에탄올에 비해 반응성이 매우 높고 독성이 강한 것으로 알려져 있다. 특히, 아세트알데하이드는 음주 후 두통을 수반하는 대표적인 화학물질로서, WHO에서도 독성을 경고한 바 있다. Among them, hangover phenomenon is known to be caused by the action of alcohol and acetaldehyde accumulated in the body. Ethanol entering the liver is converted to acetaldehyde by alcohol dehydrogenase (ADH) in the cell cytosol, and then converted to acetate by the action of aldehyde dehydrogenase (ALDH), which is converted into hepatocytes through the circulatory system. excreted out Acetaldehyde, which is produced as an initial metabolite of ethanol in the above metabolic process, is known to be highly reactive and highly toxic than ethanol. In particular, acetaldehyde is a representative chemical that accompanies a headache after drinking, and the WHO has warned of its toxicity.
정상적으로 기능하는 인체 내에는 알데히드의 산화에 관여하는 주 효소인 ALDH가 간, 콩팥, 심장 및 위를 포함한 장기와 조직에 널리 분포되어 있어, 체내에 존재하는 각종 알데하이드의 부작용에 대응할 수 있다. 그러나, ALDH가 선천적으로 부족한 사람이나, 과음 등의 요인에 의하여 ALDH 활성에 변화가 생기면, 산화되지 않은 에탄올과 활성 알데히드의 유독성에 의하여 정상적인 신진대사가 방해를 받아 숙취 현상과 각종 부작용에 대응할 수 없게 된다.In a normally functioning human body, ALDH, the main enzyme involved in the oxidation of aldehydes, is widely distributed in organs and tissues including the liver, kidneys, heart and stomach, so it can respond to the side effects of various aldehydes in the body. However, if ALDH activity is changed by a person who is congenitally deficient in ALDH or due to factors such as excessive drinking, normal metabolism is disturbed by the toxicity of unoxidized ethanol and active aldehyde, making it impossible to respond to hangovers and various side effects. do.
따라서, 알코올 섭취로 인한 숙취를 제거하고 혈중 알코올 및 아세트알데히드 농도를 감소시킬 수 있는 생약 제제 또는 인공 제제를 포함하는 제품 개발이 다양하게 이루어지고 있으며, 일례로 대한민국 특허공개 제2003-70232호에는 오수유 추출물을 함유하는 숙취 해소 및 항산화 작용을 위한 조성물이 개시되어 있다.Therefore, there are various developments of products containing herbal or artificial preparations capable of removing a hangover caused by alcohol intake and reducing blood alcohol and acetaldehyde concentrations. A composition for relieving hangover and antioxidant action containing the extract is disclosed.
검정무는 검정무 또는 블랙 래디시(Black Radish, Oriental Radish) 등으로도 불리우는 십자화과의 뿌리 채소인 무의 한 종류로서, 학명 Raphanus sativus L. var. niger로 알려져 있다. 겉면은 검은 색을 띠지만 내부는 흰색의 속살로 이루어져 있으며, 항고지혈증, 항염증, 항산화, 독소 제거 등의 다양한 생리활성을 나타내는 것으로 알려져 있다. 본 발명에서는 검정무에 포함된 성분이 혈중 알코올 농도, ADH 및 ALDH 수치 조절에 우수한 효과를 나타내는 점을 발견하여, 이를 활용한 숙취 해소용 조성물을 개발하기에 이르렀다.Black radish is a kind of radish, a root vegetable of the cruciferous family, also called black radish or black radish, and the scientific name is Raphanus sativus L. var. known as niger . The outer surface is black, but the inner white flesh is composed of white flesh, and it is known to exhibit various physiological activities such as anti-hyperlipidemia, anti-inflammatory, antioxidant, and toxin removal. In the present invention, it was found that the components contained in the black radish exhibit excellent effects on the control of blood alcohol concentration, ADH and ALDH levels, and thus, a composition for relieving a hangover was developed.
본 발명은 알코올 분해 효능이 우수한 숙취 해소용 조성물을 제공한다. The present invention provides a composition for relieving a hangover having an excellent alcohol decomposition effect.
본 발명의 숙취 해소용 조성물은 검정무 유산균 발효물을 포함한다.The composition for relieving a hangover of the present invention includes a black-free lactic acid bacteria fermented product.
본 발명에 따른 숙취 해소용 조성물은 알코올 분해 효능이 우수하고, ADH와 ALDH의 활성을 촉진시킴으로써 뛰어난 숙취 해소 효과를 발휘한다. The composition for relieving a hangover according to the present invention has excellent alcohol decomposition effect and exhibits an excellent hangover relieving effect by promoting the activity of ADH and ALDH.
도 1은 본 실시예 조성물의 농도에 따른 ADH 활성도를 나타낸 그래프이다.
도 2는 본 실시예 조성물의 농도에 따른 ALDH 활성도를 나타낸 그래프이다.
도 3은 본 실시예 조성물을 투여한 동물의 혈중 에탄올 농도를 나타낸 그래프이다.
도 4는 본 실시예 조성물을 투여한 동물의 혈중 아세트알데히드 농도를 나타낸 그래프이다.
도 5는 본 실시예 조성물을 투여한 동물의 간 조직의 ADH 활성도를 나타낸 그래프이다.
도 6은 본 실시예 조성물을 투여한 동물의 간 조직의 ALDH 활성도를 나타낸 그래프이다.
도 7은 본 실시예 조성물을 투여한 동물의 간 조직의 H&E 염색 슬라이드의 이미지를 촬영한 것이다.1 is a graph showing the ADH activity according to the concentration of the composition of the present example.
2 is a graph showing ALDH activity according to the concentration of the composition of the present example.
3 is a graph showing the blood ethanol concentration of the animals administered the composition of the present example.
4 is a graph showing the concentration of acetaldehyde in the blood of animals administered the composition of the present example.
5 is a graph showing the ADH activity of the liver tissue of the animal administered the composition of the present example.
6 is a graph showing the ALDH activity of the liver tissue of the animal administered the composition of the present example.
7 is an image of H&E-stained slides of liver tissues of animals administered with the composition of the present embodiment.
이하, 본 발명에 대하여 설명한다. 그러나, 하기 내용에 의해서만 한정되는 것은 아니며, 필요에 따라 각 구성요소가 다양하게 변형되거나 선택적으로 혼용될 수 있다. 따라서, 본 발명의 사상 및 기술범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated. However, it is not limited only by the following content, and each component may be variously modified or selectively mixed as needed. Accordingly, it should be understood to include all modifications, equivalents and substitutes included in the spirit and scope of the present invention.
본 발명의 숙취해소 조성물은 검정무를 활용한 것이며, 특히 검정무 유산균 발효물을 포함한다. 검정무를 유산균으로 발효하는 경우, 혈중 알코올 농도를 낮추고, ADH(Alcohol dehydrogenase)와 ALDH(Acetaldehyde dehydrogenase)의 활성을 촉진하는 효과가 더욱 탁월해지는 동시에, 섭취가 용이해진다.The hangover relieving composition of the present invention utilizes black radish, and in particular, includes black radish fermented lactic acid bacteria. When black radish is fermented with lactic acid bacteria, the effect of lowering the blood alcohol concentration and promoting the activities of ADH (Alcohol dehydrogenase) and ALDH (Acetaldehyde dehydrogenase) becomes more excellent, and at the same time, it is easy to consume.
일례로, 본 발명에 따른 검정무 유산균 발효물은 락토바실러스 속(Lactobacillus spp.) 유산균의 검정무 발효물을 포함한다. 상기 락토바실러스 속 유산균은 락토바실러스 플란타럼(Lactobacillus plantarum), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 헬베티쿠스(Lactobacillus helveticus) 및 락토바실러스 루테리(Lactobacillus reuteri)로 구성되는 군에서 선택된 1종 이상일 수 있다. 일례로, 상기 락토바실러스 속 유산균은 락토바실러스 플란타럼(Lactobacillus plantarum)일 수 있다. 락토바실러스 플란타럼(Lactobacillus plantarum)은 알코올 분해와 관련된 효과 외에 항산화 효능 또한 우수하여, 알코올 분해에 관한 시너지 효과가 더욱 탁월하게 발휘될 수 있다.For example, the fermented black radish lactic acid bacteria according to the present invention includes a fermented black radish of Lactobacillus spp. The Lactobacillus genus lactic acid bacteria is Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus casei ( Lactobacillus casei ), Lactobacillus helveticus ( Lactobacillus helveticus ) and at least one selected from the group consisting of Lactobacillus reuteri ( Lactobacillus reuteri ) can For example, the Lactobacillus genus lactic acid bacteria may be Lactobacillus plantarum ( Lactobacillus plantarum ). Lactobacillus plantarum ( Lactobacillus plantarum ) In addition to the effect related to alcohol decomposition, the antioxidant effect is also excellent, so that the synergistic effect on alcohol decomposition can be more excellently exhibited.
본 발명에 따른 검정무 유산균 발효물의 투여량은 성인(평균 체중 60 kg) 기준 720 내지 2,880 mg/day일 수 있다. 본 발명의 검정무 유산균 발효물이 전술한 범위로 투여되는 경우, 짧은 시간 내에 혈중 알코올 농도를 감소시키는 효과를 얻을 수 있다.The dosage of the assay-free lactic acid bacteria fermented product according to the present invention may be 720 to 2,880 mg/day based on an adult (average body weight of 60 kg). When the assay-free lactic acid bacteria fermented product of the present invention is administered in the above-mentioned range, it is possible to obtain the effect of reducing the blood alcohol concentration within a short time.
일례로, 본 발명의 숙취 해소용 조성물은 조성물 총 중량을 기준으로, 상기 검정무 유산균 발효물을 0.001 내지 10 중량% 포함할 수 있다.As an example, the composition for relieving a hangover of the present invention may include 0.001 to 10% by weight of the black-free lactic acid bacteria fermented product based on the total weight of the composition.
본 발명의 숙취 해소용 조성물은 약학적 조성물 또는 식품 조성물일 수 있다. 예를 들어, 본 발명의 숙취 해소용 조성물을 포함하는 건강식품, 예컨대 음료, 환, 젤리, 발포정 등의 형태로 제공될 수 있으나, 이에 한정되지는 않는다. The composition for relieving a hangover of the present invention may be a pharmaceutical composition or a food composition. For example, it may be provided in the form of health foods, such as beverages, pills, jellies, effervescent tablets, etc., containing the hangover relieving composition of the present invention, but is not limited thereto.
본 발명에 따른 검정무 유산균 발효물을 제조하는 방법은 특별히 한정되지 않으며, 검정무를 분쇄하는 분쇄 과정, 분쇄된 검정무에 유산균을 접종하여 발효시키는 발효 과정 및 발효된 검정무를 살균한 후 분말화하는 분말화 과정을 포함하는 방법으로 제조될 수 있다.The method for producing the fermented black radish lactic acid bacteria according to the present invention is not particularly limited, and includes a grinding process of pulverizing black radish, a fermentation process of inoculating and fermenting the pulverized black radish with lactic acid bacteria, and sterilizing and then pulverizing the fermented black radish. It may be prepared by a method including a powdering process.
상기 분쇄 과정에서, 세척된 검정무를 살균 처리한 후 분쇄할 수 있다. 살균 처리는 70 내지 120 ℃, 예를 들어 80 내지 110 ℃, 다른 예로 90 내지 100 ℃의 온도에서 수행될 수 있으며, 상기 열처리는 30분 내지 90분간 수행될 수 있다. 상기 온도보다 낮은 온도에서 열처리하는 경우 균이 완전히 제거되지 않을 수 있고, 상기 온도보다 높은 온도에서 열처리하는 경우 검정무의 알코올 분해를 위한 유효 성분이 검정무로부터 빠져나갈 수 있다.In the pulverization process, the washed black radish may be sterilized and then pulverized. Sterilization treatment may be performed at a temperature of 70 to 120 °C, for example 80 to 110 °C, in another example 90 to 100 °C, and the heat treatment may be performed for 30 minutes to 90 minutes. In the case of heat treatment at a temperature lower than the above temperature, bacteria may not be completely removed, and in the case of heat treatment at a temperature higher than the above temperature, the active ingredient for alcohol decomposition of the black radish may escape from the black radish.
상기 분쇄 과정은 분쇄된 검정무에 정제수를 혼합하고 멸균하는 멸균 과정을 더 포함할 수 있다. The grinding process may further include a sterilization process in which purified water is mixed with the crushed black radish and sterilized.
상기 멸균 과정에서, 분쇄된 검정무에 정제수를 1 : 0.5 내지 3 중량비, 예를 들어 1 : 0.7 내지 2 중량비, 다른 예로 1 : 0.85 내지 1.5 중량비로 첨가할 수 있다. 상기 비율보다 정제수를 과량으로 첨가하는 경우 멸균 과정 이후에 진행되는 발효 과정에서 1 LOT 당 투입되는 원물의 양이 적어져 발효 공정이 원활하게 이루어지지 않을 수 있고, 상기 비율보다 정제수를 소량으로 첨가하는 경우 이후의 발효 과정에서 유동성이 부족해져 발효 공정이 원활하게 이루어지지 않을 수 있다.In the sterilization process, purified water may be added to the pulverized black radish in a weight ratio of 1: 0.5 to 3, for example, 1: 0.7 to 2, in another example, 1: 0.85 to 1.5 by weight. If purified water is added in excess than the above ratio, the amount of raw material input per 1 LOT may decrease in the fermentation process proceeding after the sterilization process, so that the fermentation process may not be performed smoothly, and purified water is added in a small amount than the ratio In this case, the liquidity may be insufficient in the subsequent fermentation process, so that the fermentation process may not be performed smoothly.
상기 멸균 과정은 50 내지 150 ℃, 예를 들어 70 내지 140 ℃, 다른 예로 90 내지 130 ℃의 온도에서 가압멸균하는 것일 수 있다. 상기 온도보다 낮은 온도에서 열처리하는 경우에는 멸균 효과가 떨어질 수 있고, 상기 온도보다 높은 온도에서 열처리하는 경우에는 검정무 조직이 손상되어, 유산균에 의한 발효에 부적합해 질 수 있다. 상기 가압 멸균은 일례로 5 내지 60분간 수행될 수 있다.The sterilization process may be autoclaving at a temperature of 50 to 150 ℃, for example, 70 to 140 ℃, in another example 90 to 130 ℃. In the case of heat treatment at a temperature lower than the above temperature, the sterilization effect may be reduced, and in the case of heat treatment at a temperature higher than the above temperature, the black radish tissue may be damaged, making it unsuitable for fermentation by lactic acid bacteria. The autoclaving may be performed, for example, for 5 to 60 minutes.
상기 발효 과정에서, 멸균된 분쇄 검정무에 락토바실러스 속 유산균이 4.4 x 102 내지 4.4 x 109 CFU/100g, 예를 들어 4.4 x 105 내지 4.4 x 109 CFU/100g, 다른 예로 4.4 x 106 내지 4.4 x 107 CFU/100g 접종될 수 있다. 전술한 양보다 적게 접종하는 경우에는 충분히 발효되지 않아, 검정무나 검정무 추출물에 비해 유의미한 수준의 혈중 알코올 농도 저하 효과 및 ADH, ALDH 활성 촉진 효과를 갖는 발효물을 제조하기가 어렵고, 전술한 양보다 과량으로 접종하는 경우에는 오히려 ADH, ALDH 활성 촉진 효과가 떨어질 수 있다. In the fermentation process, sterilized ground black radish Lactobacillus genus lactic acid bacteria 4.4 x 10 2 to 4.4 x 10 9 CFU / 100g, for example, 4.4 x 10 5 to 4.4 x 10 9 CFU / 100g, another example 4.4 x 10 6 to 4.4 x 10 7 CFU/100g can be inoculated. When inoculated less than the above amount, it is not sufficiently fermented, so it is difficult to prepare a fermented product having a significant level of blood alcohol concentration lowering effect and ADH, ALDH activity promoting effect compared to black radish or black radish extract, In case of excessive inoculation, the effect of promoting ADH and ALDH activity may be reduced.
상기 발효는 20 내지 50 ℃, 예를 들어 25 내지 45 ℃, 다른 예로 32 내지 40 ℃의 온도에서 수행될 수 있다. 전술한 범위를 벗어나는 온도에서는 발효가 일어나지 못할 수 있다.The fermentation may be carried out at a temperature of 20 to 50 °C, for example, 25 to 45 °C, in another example 32 to 40 °C. Fermentation may not occur at a temperature outside the above-mentioned range.
상기 발효는 12 내지 120 시간, 예를 들어 24 내지 100 시간, 다른 예로 30 내지 72 시간 수행될 수 있다. 상기 시간보다 짧은 시간 발효하는 경우에는, 항산화 유효 성분이 충분히 형성되지 못할 수 있고, 유산균 발효물이 검정무나 검정무 추출물에 비해 유의미한 수준의 혈중 알코올 농도 저하 효과 및 ADH, ALDH 활성 촉진 효과가 나타나지 않을 수 있다. 한편, 상기 시간보다 긴 시간 발효하는 경우에는, 과발효에 의해 유효 성분과 검정무 성분이 분해되어, 혈중 알코올 농도 저하 효과 및 ADH, ALDH 활성 촉진 효과가 저하될 수 있다.The fermentation may be performed for 12 to 120 hours, for example, 24 to 100 hours, in another example 30 to 72 hours. In the case of fermentation for a shorter time than the above time, the antioxidant active ingredient may not be sufficiently formed, and the lactic acid bacterium fermented product does not show a significant level of blood alcohol concentration lowering effect and ADH and ALDH activity promoting effect compared to black radish or black radish extract. can On the other hand, in the case of fermenting for a longer time than the above time, the active ingredient and the black radish component are decomposed by overfermentation, and the blood alcohol concentration lowering effect and the ADH and ALDH activity promoting effect may be reduced.
본 발명에 사용된 균주는 예를 들어 한국미생물보존센터(KCCM)에서 분양받을 수 있으나, 상기 기관에서 분양받은 균주로 한정되지 않는다.The strain used in the present invention may be sold, for example, from the Korea Microorganism Conservation Center (KCCM), but is not limited to the strain received from the institution.
이하, 실시예를 통하여 본 발명을 보다 구체적으로 설명한다. 그러나, 하기 실시예는 본 발명의 이해를 돕기 위한 것일 뿐 어떠한 의미로든 본 발명의 범위가 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are provided to help the understanding of the present invention, and the scope of the present invention is not limited to the examples in any sense.
[제조예: 검정무 유산균 발효물 제조][Production Example: Production of black-free lactic acid bacteria fermented product]
1) 유산균 분양1) Sales of lactic acid bacteria
한국미생물보존센터(Korea Culture Center of Microorganisms, KCCM)에서 락토바실러스 플란타럼(Lactobacillus plantarum, KCCM 12116)을 분양받아 실험에 이용하였다. Lactobacillus plantarum (KCCM 12116) was purchased from the Korea Culture Center of Microorganisms (KCCM) and used for experiments.
2) 종균 배양2) Seed culture
분양받은 균주를 고체배지와 액체배지에 계대배양하여 실험에 이용하였다. 구체적으로, 분양받은 균주를 고체배지에 접종하여 인큐베이터에서 37 ℃, 24시간 배양한 후, 콜로니가 형성되면 액체배지에 접종하여 인큐베이터에서 37 ℃, 24시간 배양하여 종균 배양액을 제조하였다. 종균 배양에는 MRS 배지(Difco 사, 미국)를 사용하였다.The received strains were subcultured in a solid medium and a liquid medium and used in the experiment. Specifically, the received strain was inoculated into a solid medium and cultured at 37 ° C. in an incubator for 24 hours. When colonies were formed, inoculated into a liquid medium and cultured at 37 ° C. for 24 hours in an incubator to prepare a seed culture medium. MRS medium (Difco, USA) was used for seed culture.
3) 검정무 유산균 발효물의 제조3) Preparation of black-free lactic acid bacteria fermented product
검정무를 정제수에 세척하고, 95 ℃에서 30분 동안 열처리하여 살균한 후, 믹서를 사용하여 분쇄하였다. 상기 분쇄된 검정무와 정제수를 1:2의 중량비로 혼합한 뒤 121 ℃에서 30분간 가압 멸균한 후, 상온까지 냉각시켰다.The black radish was washed with purified water, sterilized by heat treatment at 95° C. for 30 minutes, and then pulverized using a mixer. The pulverized black radish and purified water were mixed in a weight ratio of 1:2, autoclaved at 121° C. for 30 minutes, and then cooled to room temperature.
상기 2)에서 배양된 종균 배양액을 멸균된 분쇄 검정무 혼합물의 1% 중량으로 접종한 후, 37 ℃ 인큐베이터에서 48시간 동안 진탕 배양하여 액체 발효하였다. 발효 종료 후 95 ℃ 에서 30분 동안 살균한 뒤, 발효물을 동결건조하여 분말화하였다.The seed culture solution cultured in 2) was inoculated with 1% weight of the sterilized ground black radish mixture, and then cultured with shaking in an incubator at 37° C. for 48 hours for liquid fermentation. After sterilization at 95 °C for 30 minutes after completion of fermentation, the fermented product was lyophilized and powdered.
[실험예 1: ADH 활성도 분석][Experimental Example 1: ADH activity analysis]
상기 제조예의 검정무 유산균 발효물을 정제수에 가하여 하기 표 1에 따른 농도의 스톡(stock)을 제조한 후, 이를 정제수로 희석하여 최종 시료(final)를 제작하였다. Alcohol Dehydrogenase Activity Assay Kit(sigma)와 분광 광도계를 이용하여, 각 시료의 450 ㎚에서 형성되는 NADH의 흡광도를 측정하여 알코올 탈수소효소(Alcohol dehydrogenase, ADH) 활성도를 분석하였다. 각 실험군의 반응 종료 시 최대 흡광도를 대조군의 최대 흡광도에 대한 비율로 나타내었으며, 하기 식으로 계산하였다. 흡광도는 시료 별로 3회 측정하였고, 계산된 ADH 활성도의 평균치를 하기 표 1 및 도 1에 나타내었다. After adding the fermented lactic acid bacteria assay of Preparation Example to purified water to prepare a stock having a concentration according to Table 1 below, it was diluted with purified water to prepare a final sample (final). Alcohol dehydrogenase (ADH) activity was analyzed by measuring the absorbance of NADH formed at 450 nm of each sample using Alcohol Dehydrogenase Activity Assay Kit (sigma) and a spectrophotometer. The maximum absorbance at the end of the reaction of each experimental group was expressed as a ratio to the maximum absorbance of the control group, and was calculated by the following formula. Absorbance was measured three times for each sample, and the average values of the calculated ADH activities are shown in Table 1 and FIG. 1 below.
ADH activity = (B/A) Х100ADH activity = (B/A) Х100
상기 식에서,In the above formula,
A는 대조군(검정무 발효물 비포함)의 최대 흡광도이고, A is the maximum absorbance of the control (without fermented black radish),
B는 실험군(각 시료)의 최대 흡광도이다.B is the maximum absorbance of the experimental group (each sample).
상기 표 1 및 도 1에 나타난 바와 같이, 대조군에 비해 실험군에서 ADH의 활성이 촉진됨을 확인할 수 있었다. 또한, ADH 활성 촉진 효과는 검정무 발효물의 농도가 높아질수록 증가됨을 확인할 수 있다. As shown in Table 1 and FIG. 1, it was confirmed that the activity of ADH was promoted in the experimental group compared to the control group. In addition, it can be confirmed that the ADH activity promoting effect increases as the concentration of the fermented black radish increases.
[실험예 2: ALDH 활성도 분석][Experimental Example 2: ALDH activity analysis]
상기 제조예의 검정무 유산균 발효물을 정제수에 가하여 하기 표 2에 따른 농도의 스톡(stock)을 제조한 후, 이를 정제수로 희석하여 최종 시료(final)를 제작하였다. Aldehyde Dehydrogenase Activity Colorimetric Assay Kit(sigma)와 분광 광도계를 이용하여, 각 시료의 450 ㎚에서 형성되는 NADH 흡광도를 측정하여 알데하이드 탈수소효소(Acetaldehyde dehydrogenase, ALDH) 활성도를 분석하였다. 각 실험군의 반응 종료 시 최대 흡광도를 대조군의 최대 흡광도에 대한 비율로 나타내었으며, 하기 식으로 계산하였다. 흡광도는 시료 별로 3회 측정하였고, 계산된 ALDH 활성도의 평균치를 하기 표 2 및 도 2에 나타내었다. After adding the fermented lactic acid bacteria assay of Preparation Example to purified water to prepare a stock having a concentration according to Table 2 below, it was diluted with purified water to prepare a final sample (final). Aldehyde Dehydrogenase Activity Using a Colorimetric Assay Kit (sigma) and a spectrophotometer, the absorbance of NADH formed at 450 nm of each sample was measured to analyze Acetaldehyde dehydrogenase (ALDH) activity. The maximum absorbance at the end of the reaction of each experimental group was expressed as a ratio to the maximum absorbance of the control group, and was calculated by the following formula. Absorbance was measured three times for each sample, and the average values of the calculated ALDH activities are shown in Table 2 and FIG. 2 below.
ALDH activity = (B/A) Х100ALDH activity = (B/A) Х100
상기 식에서, In the above formula,
A는 대조군(검정무 발효물 비포함)의 최대 흡광도이고, A is the maximum absorbance of the control (without fermented black radish),
B는 실험군(각 시료)의 최대 흡광도이다.B is the maximum absorbance of the experimental group (each sample).
상기 표 2 및 도 2에 나타난 바와 같이, 대조군에 비해 실험군에서 ALDH의 활성이 촉진됨을 확인할 수 있었다. 또한, ALDH 활성 촉진 효과는 검정무 발효물의 농도가 높아질수록 증가됨을 확인할 수 있다. As shown in Table 2 and FIG. 2, it was confirmed that the activity of ALDH was promoted in the experimental group compared to the control group. In addition, it can be confirmed that the ALDH activity promoting effect increases as the concentration of the fermented black radish increases.
[실험예 3: 실험 동물 처치][Experimental Example 3: Treatment of experimental animals]
오리엔트바이오(Sungnam, Korea)에서 구입한 SD 랫드(Sprague-Dawley rat, 수컷, 8주령)를 사용하여 실험하였다. 사육실의 환경은 평균 온도 22±1℃, 습도 50±10%로 유지하였고, 12시간 간격으로 명암을 조절하며 순화 기간 1주일간 사료와 물은 자유롭게 공급하였다. The experiment was conducted using SD rats (Sprague-Dawley rat, male, 8 weeks old) purchased from Orient Bio (Sungnam, Korea). The environment of the breeding room was maintained at an average temperature of 22±1℃ and humidity of 50±10%, and the light and dark was controlled at 12-hour intervals, and feed and water were freely supplied for one week during the acclimatization period.
실험 동물을 대조군, 저용량군 및 고용량군으로 나누었고(각 군당 24 마리), 에탄올 투여 전에 18시간 동안 절식 시켰다. 알코올 투여 30분 전에 대조군에는 식염수 2 ml/kg, 저용량군에는 상기 제조예의 락토바실러스 플란타럼 검정무 발효물 75 mg/kg, 고용량군에는 상기 제조예의 락토바실러스 플란타럼 검정무 발효물 300 mg/kg을 경구투여 하였고, 30분 뒤 모든 동물에 25% 에탄올(Merck, Darmstadt, Germany)을 4 g/kg 용량으로 경구투여 하였다. The experimental animals were divided into a control group, a low-dose group and a high-dose group (24 animals in each group), and were fasted for 18 hours before ethanol administration. 30 minutes before alcohol administration, saline 2 ml/kg for the control group, 75 mg/kg of the Lactobacillus plantarum test radish fermented product of the Preparation Example in the low-dose group, and 300 mg of the Lactobacillus plantarum test radish fermented product of the Preparation Example in the high-dose group. /kg was orally administered, and after 30 minutes, 25% ethanol (Merck, Darmstadt, Germany) was orally administered to all animals at a dose of 4 g/kg.
에탄올 투여 1, 2, 4시간 후 동물을 이소플루란(Isoflurane, Virbac, Carros, France)을 이용하여 마취한 후, 복강을 열어 복대정맥에서 전혈을 채취하고 간 조직을 적출하여 일부는 -70℃에 보관하고, 나머지는 10% 중성 포르말린에 고정하였다. 채취한 전혈은 3,000 rpm, 4℃에서 15분간 원심 분리한 후 혈청을 분리하여 -70℃에 보관하였다.After 1, 2, and 4 hours of ethanol administration, the animal is anesthetized using isoflurane (Isoflurane, Virbac, Carros, France), the abdominal cavity is opened to collect whole blood from the abdominal vena cava , and the remainder was fixed in 10% neutral formalin. The collected whole blood was centrifuged at 3,000 rpm and 4°C for 15 minutes, and serum was separated and stored at -70°C.
[실험예 4: 혈중 에탄올 및 아세트알데히드 함량 측정][Experimental Example 4: Measurement of ethanol and acetaldehyde content in blood]
시간 별로 채취한 혈청에서 에탄올 및 아세트알데히드 함량을 측정하였다. 에탄올은 혈액생화학분석기(TBA-120FR, Toshiba, Tokyo, Japan)로 측정하였고, 아세트알데히드는 Acetaldehyde assay kit(EACT-100, Biovision, Milpitas, CA, USA)를 이용하여 반응시킨 후, 분광광도계(Synergy H4, Biotek, Winooski, VT, USA)를 이용하여 565 nm에서 측정하였다. 측정값은 평균값 ± 표준편차로 표시하였다. 대조군과 실험군 간의 통계학적 유의성 검정은 student's t-test를 사용하였고, P값이 0.05 미만일 때 유의한 것으로 판정하였다.Ethanol and acetaldehyde contents were measured in the serum collected by time. Ethanol was measured with a blood biochemical analyzer (TBA-120FR, Toshiba, Tokyo, Japan), and acetaldehyde was reacted using an Acetaldehyde assay kit (EACT-100, Biovision, Milpitas, CA, USA), followed by a spectrophotometer (Synergy). H4, Biotek, Winooski, VT, USA) was used to measure at 565 nm. Measured values were expressed as mean ± standard deviation. Student's t-test was used to test for statistical significance between the control group and the experimental group, and it was determined to be significant when the P value was less than 0.05.
도 3에 나타난 바와 같이, 혈중 에탄올 농도를 분석한 결과, 대조군에서는 알코올 투여 1시간 후에 113.27 mg/dl로 가장 높게 나타났고, 2시간 후에는 59.00 mg/dl, 4시간 후에는 23.85 mg/dl로 감소하였다. 저농도군에서는 알코올 투여 1시간 후 50.07 mg/dl로 대조군 대비 유의하게 감소하였고, 2시간 후에는 7.37 mg/dl로 대조군 대비 유의하게 감소하였고, 4시간 후에는 11.22 mg/dl 농도를 보였다. 고농도군에서는 알코올 투여 1시간 후에 61.32 mg/dl로 대조군 대비 유의하게 감소하였고, 2시간 후에는 59.30 mg/dl 농도를 보였고, 4시간 후에는 5.60 mg/dl로 대조군 대비 유의하게 감소하였다. As shown in FIG. 3 , as a result of analyzing the blood ethanol concentration, the control group showed the highest level of 113.27 mg/dl 1 hour after alcohol administration, 59.00 mg/dl after 2 hours, and 23.85 mg/dl after 4 hours. decreased. In the low concentration group, 1 hour after alcohol administration, it was significantly reduced to 50.07 mg/dl compared to the control group, and after 2 hours it was significantly decreased to 7.37 mg/dl compared to the control group, and after 4 hours, the concentration was 11.22 mg/dl. In the high concentration group, the concentration was significantly reduced to 61.32 mg/dl after 1 hour of alcohol administration, compared to the control group, showed a concentration of 59.30 mg/dl after 2 hours, and decreased significantly to 5.60 mg/dl after 4 hours compared to the control group.
도 4에 나타난 바와 같이, 혈중 아세트알데히드 농도를 분석한 결과, 대조군에서는 알코올 투여 1시간 후에 155.05 uM 농도를 나타내었고, 2시간 후에는 169.58 uM, 4시간 후에는 131.31 uM로 약간 감소하였다. 저농도군에서는 알코올 투여 1시간 후 155.58 uM, 2시간 후에는 135.54 uM, 4시간 후에는 122.93 uM 농도를 보였다. 고농도군에서는 알코올 투여 1시간 후에 179.65 uM, 2시간 후에는 94.36 uM, 4시간 후에는 48.27 uM로 대조군 대비 유의하게 감소하였다.As shown in FIG. 4 , as a result of analyzing the blood acetaldehyde concentration, the control group showed a concentration of 155.05 uM 1 hour after alcohol administration, 169.58 uM after 2 hours, and 131.31 uM after 4 hours. In the low concentration group, the concentration of alcohol was 155.58 uM after 1 hour, 135.54 uM after 2 hours, and 122.93 uM after 4 hours. In the high concentration group, 179.65 uM after 1 hour of alcohol administration, 94.36 uM after 2 hours, and 48.27 uM after 4 hours were significantly reduced compared to the control group.
[실험예 5: 간 조직의 ADH 및 ALDH 활성도 측정][Experimental Example 5: Measurement of ADH and ALDH Activity in Liver Tissue]
부검 후 -70℃ 보관 중인 간 조직을 50 mg씩 나누어 ADH 및 ALDH 활성도를 측정하였다. 각각 ADH activity colorimetric assay kit(K787-100, Biovision, Milpitas, CA, USA) 및 ALDH activity colorimetric assay kit(K787-100, Biovision, Milpitas, CA, USA)를 이용하여 반응시킨 후, 분광광도계(Synergy H4, Biotek, Winooski, VT, USA)를 이용하여 450 nm에서 각 효소의 활성도를 측정하였다. 측정값은 평균값 ± 표준편차로 표시하였다. 대조군과 실험군 간의 통계학적 유의성 검정은 student's t-test를 사용하였고, P값이 0.05 미만일 때 유의한 것으로 판정하였다.After autopsy, liver tissue stored at -70°C was divided into 50 mg each to measure ADH and ALDH activity. After reacting using ADH activity colorimetric assay kit (K787-100, Biovision, Milpitas, CA, USA) and ALDH activity colorimetric assay kit (K787-100, Biovision, Milpitas, CA, USA), respectively, spectrophotometer (Synergy H4) , Biotek, Winooski, VT, USA) was used to measure the activity of each enzyme at 450 nm. Measured values were expressed as mean ± standard deviation. Student's t-test was used to test for statistical significance between the control group and the experimental group, and it was determined to be significant when the P value was less than 0.05.
도 5에 나타난 바와 같이, 간 조직의 ADH 활성도를 측정한 결과, 대조군에서는 108.43 mU/ml, 저농도군에서는 123.09 mU/ml, 고농도군에서는 204.35 mU/ml로 대조군 대비 유의적으로 증가하였다. 도 6에 나타난 바와 같이, 간 조직의 ALDH 활성도를 측정한 결과, 대조군에서는 8.55 mU/ml, 저농도군에서는 13.23 mU/ml, 고농도군에서는 19.42 mU/ml로 대조군 대비 유의적으로 증가하였다. As shown in FIG. 5 , as a result of measuring the ADH activity of liver tissue, it was 108.43 mU/ml in the control group, 123.09 mU/ml in the low concentration group, and 204.35 mU/ml in the high concentration group, which was significantly increased compared to the control group. As shown in FIG. 6 , as a result of measuring the ALDH activity of liver tissue, it was significantly increased compared to the control group to 8.55 mU/ml in the control group, 13.23 mU/ml in the low concentration group, and 19.42 mU/ml in the high concentration group.
상기 도 3 내지 도 6의 결과로부터, 본 발명에 따른 검정무 발효 추출물이 ADH, ALDH의 활성도를 증가시켜, 에탄올 흡수 후 에탄올과 아세트알데히드 분해에 영향을 주는 것을 확인하였다.From the results of FIGS. 3 to 6 , it was confirmed that the fermented black radish extract according to the present invention increased the activity of ADH and ALDH, thereby affecting the decomposition of ethanol and acetaldehyde after ethanol absorption.
[실험예 6: 간 조직의 조직병리학적 평가][Experimental Example 6: Histopathological evaluation of liver tissue]
10% 중성 포르말린에 고정한 간 조직을 조직처리기(Excelsior ES, ThermoFisher Scientific, Waltham, MA, USA)를 이용하여 탈수, 투명화, 파라핀 침투를 시킨 후, 조직포매기(Histostar, ThermoFisher Scientific, Waltham, MA, USA)를 이용하여 파라핀 블록을 제작하였다. 파라핀 블록을 4 um로 박절하여 슬라이드 제작 후, 자동 염색 봉입기(Coverstainer, Aglient, Santa Clara, CA, USA)를 이용하여 헤마톡실린 에오신(H&E) 염색을 하였다. 슬라이드 스캐너(Panoramic SCAN, 3DHistech, Budapest, Hungary)를 이용하여, H&E 염색 슬라이드의 이미지를 촬영하였다.Liver tissue fixed in 10% neutral formalin was dehydrated, cleared, and paraffin-infiltrated using a tissue processor (Excelsior ES, ThermoFisher Scientific, Waltham, MA, USA), followed by tissue embedding (Histostar, ThermoFisher Scientific, Waltham, MA, USA) was used to prepare paraffin blocks. After the paraffin block was cut into 4 µm slices, slides were prepared, and hematoxylin eosin (H&E) staining was performed using an automatic staining machine (Coverstainer, Aglient, Santa Clara, CA, USA). Using a slide scanner (Panoramic SCAN, 3DHistech, Budapest, Hungary), images of H&E-stained slides were taken.
외부 물질에 의한 간 손상이 일어나게 되면 간세포(hepatocyte)의 변성(degeneration), 지방구축적(lipidosis), 섬유화(fibrosis), 심하면 괴사(necrosis)가 진행되는데, 이 경우 조직병리학적으로 관찰이 가능하다. 도 7에 나타난 바와 같이, 간 조직의 조직병리학적 평가 결과, 저농도군과 고농도군에서 대조군 대비 모두 특이적인 변화를 보이지 않았고, 상기 결과로부터 본 발명에 따른 검정무 유산균 발효물이 독성학적인 변화를 일으키지 않는 것을 확인하였다.When the liver is damaged by foreign substances, degeneration of hepatocytes, lipidosis, fibrosis, and, in severe cases, necrosis proceeds, and in this case, histopathological observation is possible. . As shown in FIG. 7 , as a result of histopathological evaluation of liver tissue, both the low concentration group and the high concentration group did not show specific changes compared to the control group, and from the above results, the assay-free lactic acid bacteria fermented according to the present invention did not cause toxicological changes. confirmed that it is not.
[실험예 7: 혈청 생화학 분석][Experimental Example 7: Serum Biochemical Analysis]
에탄올 투여 4시간 후 동물에서 확보한 혈청으로 16가지 항목(Sodium, Potassium, Chloride, Total protein, Albumin, Blood urea nitrogen, Creatinine, Glucose, Total bilirubin, Calcium, Phosphorus, Total cholesterol, Triglyceride, Aspartate transaminase, Alanine aminotransferase, Alkaline phosphatase)을 혈액생화학분석기(TBA-120FR, Toshiba, Tokyo, Japan)로 측정하였다. 측정값은 평균값 ± 표준편차로 표시하였다. 대조군과 실험군 간의 통계학적 유의성 검정은 student's t-test를 사용하였고, P값이 0.05 미만일 때 유의한 것으로 판정하였다.16 items (Sodium, Potassium, Chloride, Total protein, Albumin, Blood urea nitrogen, Creatinine, Glucose, Total bilirubin, Calcium, Phosphorus, Total cholesterol, Triglyceride, Aspartate transaminase, Alanine aminotransferase and alkaline phosphatase) were measured with a blood biochemical analyzer (TBA-120FR, Toshiba, Tokyo, Japan). Measured values were expressed as mean ± standard deviation. Student's t-test was used to test for statistical significance between the control group and the experimental group, and it was determined to be significant when the P value was less than 0.05.
외부 물질에 의한 간 손상이 일어나게 되면 간세포(hepatocyte)의 변성(degeneration), 지방구축적(lipidosis), 섬유화(fibrosis), 심하면 괴사(necrosis)가 진행되는데, 이 경우 세포 내의 효소가 혈중으로 유출되기 때문에 혈중 Aspartate transaminase, Alanine aminotransferase 효소의 농도는 간 손상의 지표가 된다. 상기 표 3에 나타난 바와 같이, 대조군 대비 저농도군과 고농도군의 혈청 생화학분석에서 간과 관련한 Aspartate transaminase, Alanine aminotransferase 뿐만 아니라 측정 항목 전부에서 유의적인 변화를 나타내지 않았다. 상기 결과로부터 본 발명의 검정무 발효 추출물이 독성학적인 변화를 일으키지 않는 것을 확인하였다.When the liver is damaged by foreign substances, degeneration of hepatocytes, lipidosis, fibrosis, and, in severe cases, necrosis proceed. Therefore, the concentration of aspartate transaminase and alanine aminotransferase in the blood is an indicator of liver damage. As shown in Table 3 above, in the serum biochemical analysis of the low concentration group and the high concentration group compared to the control group, there was no significant change in all measurement items as well as liver-related aspartate transaminase and alanine aminotransferase. From the above results, it was confirmed that the fermented extract of the present invention does not cause toxicological changes.
Claims (10)
숙취 해소용 조성물 총 중량을 기준으로, 상기 검정무 유산균 발효물을 0.001 내지 10 중량% 포함하는 숙취 해소용 조성물. A composition for relieving a hangover comprising a black-free lactic acid bacteria fermented product,
Based on the total weight of the composition for relieving a hangover, a composition for relieving a hangover comprising 0.001 to 10% by weight of the black-free lactic acid bacteria fermented product.
상기 분쇄된 검정무에 락토바실러스 속 유산균을 접종하여 발효시키는 발효 과정; 및
상기 발효된 검정무를 살균한 후 분말화하는 분말화 과정을 포함하는 검정무 유산균 발효물을 포함하는 숙취 해소용 조성물의 제조방법으로서,
숙취 해소용 조성물 총 중량을 기준으로, 상기 검정무 유산균 발효물을 0.001 내지 10 중량% 포함하는 숙취 해소용 조성물의 제조방법. grinding process of grinding black radish;
A fermentation process of inoculating and fermenting the pulverized black radish with Lactobacillus genus lactic acid bacteria; and
As a method for preparing a composition for relieving a hangover comprising a fermented product of black radish lactic acid bacteria comprising a powdering process of sterilizing the fermented black radish and then powdering,
Based on the total weight of the composition for relieving a hangover, the method for preparing a composition for relieving a hangover comprising 0.001 to 10% by weight of the black-free lactic acid bacteria fermented product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210071759A KR102413920B1 (en) | 2021-06-02 | 2021-06-02 | Hangover-relieving composition comprising fermented black radish |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210071759A KR102413920B1 (en) | 2021-06-02 | 2021-06-02 | Hangover-relieving composition comprising fermented black radish |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102413920B1 true KR102413920B1 (en) | 2022-06-30 |
Family
ID=82214888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210071759A KR102413920B1 (en) | 2021-06-02 | 2021-06-02 | Hangover-relieving composition comprising fermented black radish |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102413920B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102002284B1 (en) * | 2018-05-31 | 2019-07-23 | 콜마비앤에이치 주식회사 | Composition for Improving Liver Function Having Fermented Materials of Black Radish from Jeju Island by Lactobacillus spp. and Method for Preparation of Fermented Materials of Black Radish from Jeju Island |
KR20190138114A (en) * | 2018-06-04 | 2019-12-12 | 제주대학교 산학협력단 | Composition comprising fermented product of Raphanus sativus L. var niger for treating, improving or treating liver injury and liver dysfunction |
-
2021
- 2021-06-02 KR KR1020210071759A patent/KR102413920B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102002284B1 (en) * | 2018-05-31 | 2019-07-23 | 콜마비앤에이치 주식회사 | Composition for Improving Liver Function Having Fermented Materials of Black Radish from Jeju Island by Lactobacillus spp. and Method for Preparation of Fermented Materials of Black Radish from Jeju Island |
KR20190138114A (en) * | 2018-06-04 | 2019-12-12 | 제주대학교 산학협력단 | Composition comprising fermented product of Raphanus sativus L. var niger for treating, improving or treating liver injury and liver dysfunction |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140341873A1 (en) | New Strain of Cadmium-Removing Lactobacillus plantarum Bacterium, and Uses of the Same | |
CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
EP2271367B1 (en) | Mineral absorption accelerator and iron deficiency anemia improver or food composition | |
CN107549817B (en) | Moringa oleifera natural organic calcium and preparation method thereof | |
KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
US20120184620A1 (en) | Antioxidant composition | |
RU2671221C2 (en) | Compositions comprising mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing effects of alcohol | |
US20200330530A1 (en) | Hepatoprotection food composition and pharmaceutical composition with strains of lactic acid bacteria | |
JP4119656B2 (en) | Antioxidant | |
TW202302134A (en) | Use of noni fruit ferment in the manufacture of product for improving body shape and improving skin condition | |
KR102413920B1 (en) | Hangover-relieving composition comprising fermented black radish | |
JP2006180868A (en) | Method for producing chlorella fermented food | |
KR102002284B1 (en) | Composition for Improving Liver Function Having Fermented Materials of Black Radish from Jeju Island by Lactobacillus spp. and Method for Preparation of Fermented Materials of Black Radish from Jeju Island | |
KR101592938B1 (en) | Anti-obesity health functional fermented soybean beverage having flavored taste | |
KR20150017880A (en) | Composition for detoxification or relieving hangover comprising fermented natural plant as effective component | |
KR100732582B1 (en) | Process for preparing a fermentation food containing chlorella | |
JP2007126399A (en) | Composition for increasing glutathione | |
Mohamed et al. | Characterization of stirred yoghurt enriched with probiotics and beetroot and its therapeutic potential in experimental type 2 diabetes | |
JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
KR102678297B1 (en) | Fermentation composition for promoting height growth comprising fermented oyster extract | |
KR101672098B1 (en) | Composition for removing hangover comprising fermented rice rinse water | |
KR100552144B1 (en) | Double-fermented bio-zyme liquid and functional beverage with using the same | |
KR20060065753A (en) | Lactobacillus fermentum and dairy products and health-promoting food containing the same | |
CN112806462A (en) | Composition with effects of preventing hangover, relieving alcoholism and protecting liver and preparation method thereof | |
WO2000069453A1 (en) | Sod-like composition and blood-pressure controlling agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |